文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

美国284家医院采用电子监测标准统计非呼吸机相关医院获得性肺炎的发生率与结局

Incidence and Outcomes of Non-Ventilator-Associated Hospital-Acquired Pneumonia in 284 US Hospitals Using Electronic Surveillance Criteria.
PubMed 文献 · JAMA Netw Open · 2023-05-01
一句话结论电子监测标准下NV-HAP约见于1/200住院,院内粗死亡率22.4%,估计占全部院内死亡的7.3%。

该回顾性队列研究将NV-HAP临床监测标准应用于美国284家医院2015-2020年(退伍军人健康管理局)和2018-2020年(HCA Healthcare)的电子健康记录,纳入6 022 185例次住院,识别出32 797例NV-HAP事件(每100例住院0.55例,每1000患者日0.96例)。NV-HAP患者院内粗死亡率为22.4%,显著高于全部住院的1.9%;中位住院时间16天 vs 4天;74.9%的病例发生在ICU之外。经逆概率加权估计,NV-HAP占全部院内死亡的7.3%(95%CI 7.1%-7.5%)。作者认为应系统监测NV-HAP、定义预防最佳实践并追踪其效果。

要点

  • NV-HAP发生率为每100例住院0.55例(95%CI 0.54-0.55),每1000患者日0.96例(95%CI 0.95-0.97)。
  • NV-HAP患者院内粗死亡率为22.4%(7361/32797),全部住院为1.9%(115530/6022185);8.0%(12449例)出院转临终关怀。
  • NV-HAP患者中位住院时间16天(IQR 11-26),全部住院为4天(IQR 3-6)。
  • 74.9%(24568例)的NV-HAP发生在ICU之外,提示非ICU病区是主要发生场景。
  • 逆概率加权估计NV-HAP占全部院内死亡的7.3%(95%CI 7.1%-7.5%)。

适用人群与场景

  • 2015-2020年退伍军人健康管理局医院及2018-2020年HCA Healthcare医院收治的成年住院患者,共6 022 185例次住院。
  • NV-HAP患者中位年龄66岁(IQR 54-75),26.1%(1 829 475例)为女性,中位合并症数6种(IQR 4-7)。
  • NV-HAP患者合并充血性心力衰竭29.5%(9680例)、神经系统疾病25.2%(8255例)、慢性肺病19.6%(6439例)、癌症16.7%(5467例)。

诊断标准与关键阈值

  • NV-HAP电子监测标准:未接受机械通气的患者氧合持续恶化2天或以上,同时满足体温或白细胞计数异常、完成胸部影像学检查、新用抗生素3天或以上。

研究设计与关键结果

  • 研究类型:回顾性队列研究,将NV-HAP临床监测标准应用于美国284家医院的电子健康记录。
  • 共纳入6 022 185例次住院,识别出32 797例NV-HAP事件,发生率为每100例住院0.55例(95%CI 0.54-0.55),每1000患者日0.96例(95%CI 0.95-0.97)。
  • NV-HAP患者院内粗死亡率为22.4%(7361/32797),全部住院为1.9%(115530/6022185);8.0%(12449例)出院转临终关怀。
  • NV-HAP患者中位住院时间16天(IQR 11-26),全部住院为4天(IQR 3-6)。
  • 74.9%(24568例)的NV-HAP发生在ICU之外。
  • 病历复核:250例符合监测标准的患者中,202例(81%)经复核者或床旁临床医生确认肺炎。
  • 逆概率加权估计NV-HAP占全部院内死亡的7.3%(95%CI 7.1%-7.5%);包含NV-HAP事件的总体住院患者院内死亡风险为1.87%,排除NV-HAP事件为1.73%,风险比0.927(95%CI 0.925-0.929)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,这些发现强调需要系统监测NV-HAP、定义预防最佳实践并追踪其影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Non-ventilator-associated hospital-acquired pneumonia (NV-HAP) is a common and deadly hospital-acquired infection. However, inconsistent surveillance methods and unclear estimates of attributable mortality challenge prevention.

OBJECTIVE: To estimate the incidence, variability, outcomes, and population attributable mortality of NV-HAP.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study retrospectively applied clinical surveillance criteria for NV-HAP to electronic health record data from 284 US hospitals. Adult patients admitted to the Veterans Health Administration hospital from 2015 to 2020 and HCA Healthcare hospitals from 2018 to 2020 were included. The medical records of 250 patients who met the surveillance criteria were reviewed for accuracy.

EXPOSURES: NV-HAP, defined as sustained deterioration in oxygenation for 2 or more days in a patient who was not ventilated concurrent with abnormal temperature or white blood cell count, performance of chest imaging, and 3 or more days of new antibiotics.

MAIN OUTCOMES AND MEASURES: NV-HAP incidence, length-of-stay, and crude inpatient mortality. Attributable inpatient mortality by 60 days follow-up was estimated using inverse probability weighting, accounting for both baseline and time-varying confounding.

RESULTS: Among 6 022 185 hospitalizations (median [IQR] age, 66 [54-75] years; 1 829 475 [26.1%] female), there were 32 797 NV-HAP events (0.55 per 100 admissions [95% CI, 0.54-0.55] per 100 admissions and 0.96 per 1000 patient-days [95% CI, 0.95-0.97] per 1000 patient-days). Patients with NV-HAP had multiple comorbidities (median [IQR], 6 [4-7]), including congestive heart failure (9680 [29.5%]), neurologic conditions (8255 [25.2%]), chronic lung disease (6439 [19.6%]), and cancer (5,467 [16.7%]); 24 568 cases (74.9%) occurred outside intensive care units. Crude inpatient mortality was 22.4% (7361 of 32 797) for NV-HAP vs 1.9% (115 530 of 6 022 185) for all hospitalizations; 12 449 (8.0%) were discharged to hospice. Median [IQR] length-of-stay was 16 (11-26) days vs 4 (3-6) days. On medical record review, pneumonia was confirmed by reviewers or bedside clinicians in 202 of 250 patients (81%). It was estimated that NV-HAP accounted for 7.3% (95% CI, 7.1%-7.5%) of all hospital deaths (total hospital population inpatient death risk of 1.87% with NV-HAP events included vs 1.73% with NV-HAP events excluded; risk ratio, 0.927; 95% CI, 0.925-0.929).

CONCLUSIONS AND RELEVANCE: In this cohort study, NV-HAP, which was defined using electronic surveillance criteria, was present in approximately 1 in 200 hospitalizations, of whom 1 in 5 died in the hospital. NV-HAP may account for up to 7% of all hospital deaths. These findings underscore the need to systematically monitor NV-HAP, define best practices for prevention, and track their impact.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Jones BE, Sarvet AL, Ying J, et al. Incidence and Outcomes of Non-Ventilator-Associated Hospital-Acquired Pneumonia in 284 US Hospitals Using Electronic Surveillance Criteria. JAMA Netw Open. 2023. PMID: 37200031. doi:10.1001/jamanetworkopen.2023.14185

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。